Pernod Ricard Korea has unveiled Redbreast 15 Year Old, a new variant of its Irish whiskey brand. The launch is aimed at meeting the growing demand for non-Scotch whiskeys in the rapidly expanding domestic market.
Redbreast 15 Year Old is crafted from whiskey that has been matured for a minimum of 15 years. The distiller uses premium bourbon casks and sherry casks for separate maturation, resulting in a more aged and flavorful profile. The master blender carefully selects and blends both first-fill and refill casks to create a distinctive aroma of berry fruit with subtle spice.
Korea Times noted that the distilling process of Redbreast 15 Year Old adheres to the traditional Irish "single pot still" method, which has been passed down since the 1800s. Utilizing a copper pot still and a combination of unmalted barley and germinated barley, the whiskey undergoes triple distillation for exceptional quality and character.
Earlier this year, Pernod Ricard Korea introduced Redbreast 12 Year Old in Korea for the first time, gaining recognition for its smooth and traditional Irish pot still whiskey. The newly launched 15 Year Old variation offers a spicier profile, coupled with a higher alcohol content of 46 percent, compared to the 12 Year Old's fruitier notes and 40 percent alcohol content.
A Surge in Korean Whiskey Consumption
According to Euromonitor International, Korea experienced a remarkable 46 percent increase in annual whiskey consumption in 2022, surpassing other countries worldwide. This surge is attributed to the preferences of millennials and Generation Z, who seek moderate drinking experiences and affordable luxuries following the impact of COVID-19.
Despite the prevailing preference for single-malt Scotch among Korean consumers, Pernod Ricard Korea anticipates a growing interest in Irish whiskey. According to the Korea Herald. International Wine & Spirit Record's data showed a significant 40.6 percent increase in non-Scotch whiskey sales in the Korean market over the past five years.
The Inspiration Behind Redbreast 15 Year Old
Billy Leighton, the master blender at Pernod Ricard's Irish whiskey distillery, expressed their mission to inspire Korean consumers, particularly the younger generation, who are eager for new experiences, with their Irish whiskey offerings.
To showcase Redbreast 15 Year Old and the new craft bourbon, Rabbit Hole Dareringer, Pernod Ricard Korea is hosting an exhibition at the Maison LeCercle lounge in Gangnam-gu, Seoul, until November 18. The event aims to attract local bartenders and whiskey enthusiasts alike.
Redbreast 15 Year Old is available at a net price of 160,000 won ($120) in select malt bars, key department stores, major discount retailers, and specialized liquor shops throughout South Korea. Whiskey enthusiasts can now explore the exceptional flavors and craftsmanship of this new addition to the Korean market.
Photo: Redbreast Whiskey Website


Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



